#United States #Cambridge #Obesity Treatment #MetaVia Inc #DA-1726

MetaVia Inc. Reports Progress in Q3 2025

In its recent release dated November 6, 2025, MetaVia Inc. (Nasdaq: MTVA), a leader in clinical-stage biotechnology focusing on transforming the treatment of cardiometabolic diseases, disclosed its financial results for the third quarter ended September 30, 2025, alongside pivotal developments regarding its drug candidate DA-1726 for obesity treatment.

Strong Financial Overview

During the third quarter of 2025, MetaVia reported a net loss of $3.4 million, translating to $0.14 per share, a notable improvement from a loss of $5.7 million ($0.55 per share) recorded in the same quarter the previous year. The company ended the quarter with $14.3 million in cash reserves, projected to sustain its operations into 2026.

Chief Executive Officer Hyung Heon Kim emphasized that the quarter was characterized by continued progress in their cardiometabolic product line, particularly marked by promising updates related to DA-1726. This innovative drug is recognized as a dual agonist of oxyntomodulin and aims to combat obesity by potentially lowering body weight and waist circumference with a favorable safety profile, shown through Phase 1 clinical trials.

Milestones of DA-1726

Recent data from the Phase 1 trial, presented at ObesityWeek® 2025, underscored a significant safety and tolerability profile, revealing that participants experienced an average body weight reduction of 6.3% and a waist circumference decline of 3.9 inches following treatment. The pharmacokinetic data suggested that the drug could support once-weekly dosing, with an 80-hour half-life, affirming its viability as a long-term treatment option.

The company has extended the Phase 1 trial to include an eight-week, 48 mg cohort, focusing on the non-titrated maximum tolerated dose and long-term efficacy and safety. Expected results from this cohort are anticipated by the end of 2025, which will provide further insight into DA-1726's potential as a cutting-edge treatment solution for obesity.

Advancements in Vanoglipel (DA-1241)

In addition to DA-1726, MetaVia provided updates on its other key asset, vanoglipel (DA-1241), designed as a GPR119 agonist targeting metabolic dysfunction-associated steatohepatitis (MASH). In Phase 2a trials, vanoglipel showcased a meaningful reduction in liver fat and inflammation, which are fundamental in tackling MASH. Presentation of full data from this trial is scheduled for the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025.

The dual mechanism of action of vanoglipel also implies promising therapeutic benefits that encompass glucose regulation while safeguarding liver health. A meeting with the FDA is set for the first half of 2026 to discuss the next phase of clinical development for vanoglipel.

Quarterly Highlights and Corporate Strategy

Among the key highlights of Q3 2025, the collaboration with Syntekabio, Inc. was announced to leverage AI in drug discovery, aiming to enhance therapeutic profiles beyond the scope of current targets. This strategic partnership is intended to accelerate MetaVia’s development efforts, ensuring a broader impact on the market.

In terms of expenses, the company reported a significant reduction in research and development expenses, totaling approximately $1.9 million for Q3 2025, down from $4.5 million the prior year. This decline is reflective of lower direct costs tied to the development activities surrounding vanoglipel and DA-1726.

To sum up, MetaVia Inc. has demonstrated resilience and forward momentum in its mission to combat cardiometabolic diseases through innovative therapies. With the impressive early results of DA-1726 and ongoing advancements in vanoglipel, the company is poised for a potentially transformative impact on obesity treatment. Investors and stakeholders alike will be eagerly awaiting the results from ongoing trials as MetaVia continues on its promising trajectory.